Research ExplorerPublicationsThe comorbidity and co-medication profile of patients with p...

The comorbidity and co-medication profile of patients with progressive supranuclear palsy

Standard

The comorbidity and co-medication profile of patients with progressive supranuclear palsy. / Greten, Stephan; Wegner, Florian; Jensen, Ida; Krey, Lea; Rogozinski, Sophia; Fehring, Meret; Heine, Johanne; Doll-Lee, Johanna; Pötter-Nerger, Monika; Zeitzschel, Molly; Hagena, Keno; Pedrosa, David J; Eggers, Carsten; Bürk, Katrin; Trenkwalder, Claudia; Claus, Inga; Warnecke, Tobias; Süß, Patrick; Winkler, Jürgen; Gruber, Doreen; Gandor, Florin; Berg, Daniela; Paschen, Steffen; Classen, Joseph; Pinkhardt, Elmar H; Kassubek, Jan; Jost, Wolfgang H; Tönges, Lars; Kühn, Andrea A; Schwarz, Johannes; Peters, Oliver; Dashti, Eman; Priller, Josef; Spruth, Eike J; Krause, Patricia; Spottke, Annika; Schneider, Anja; Beyle, Aline; Kimmich, Okka; Donix, Markus; Haussmann, Robert; Brandt, Moritz; Dinter, Elisabeth; Wiltfang, Jens; Schott, Björn H; Zerr, Inga; Bähr, Mathias; Buerger, Katharina; Janowitz, Daniel; Perneczky, Robert; Rauchmann, Boris-Stephan; Weidinger, Endy; Levin, Johannes; Katzdobler, Sabrina; Düzel, Emrah; Glanz, Wenzel; Teipel, Stefan; Kilimann, Ingo; Prudlo, Johannes; Gasser, Thomas; Brockmann, Kathrin; Hoffmann, Daniel C; Klockgether, Thomas; Krause, Olaf; Heck, Johannes; Höglinger, Günter U; Klietz, Martin.

In: J NEUROL, Vol. 271, No. 2, 02.2024, p. 782–793.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Greten, S, Wegner, F, Jensen, I, Krey, L, Rogozinski, S, Fehring, M, Heine, J, Doll-Lee, J, Pötter-Nerger, M, Zeitzschel, M, Hagena, K, Pedrosa, DJ, Eggers, C, Bürk, K, Trenkwalder, C, Claus, I, Warnecke, T, Süß, P, Winkler, J, Gruber, D, Gandor, F, Berg, D, Paschen, S, Classen, J, Pinkhardt, EH, Kassubek, J, Jost, WH, Tönges, L, Kühn, AA, Schwarz, J, Peters, O, Dashti, E, Priller, J, Spruth, EJ, Krause, P, Spottke, A, Schneider, A, Beyle, A, Kimmich, O, Donix, M, Haussmann, R, Brandt, M, Dinter, E, Wiltfang, J, Schott, BH, Zerr, I, Bähr, M, Buerger, K, Janowitz, D, Perneczky, R, Rauchmann, B-S, Weidinger, E, Levin, J, Katzdobler, S, Düzel, E, Glanz, W, Teipel, S, Kilimann, I, Prudlo, J, Gasser, T, Brockmann, K, Hoffmann, DC, Klockgether, T, Krause, O, Heck, J, Höglinger, GU & Klietz, M 2024, 'The comorbidity and co-medication profile of patients with progressive supranuclear palsy', J NEUROL, vol. 271, no. 2, pp. 782–793. https://doi.org/10.1007/s00415-023-12006-4

APA

Greten, S., Wegner, F., Jensen, I., Krey, L., Rogozinski, S., Fehring, M., Heine, J., Doll-Lee, J., Pötter-Nerger, M., Zeitzschel, M., Hagena, K., Pedrosa, D. J., Eggers, C., Bürk, K., Trenkwalder, C., Claus, I., Warnecke, T., Süß, P., Winkler, J., ... Klietz, M. (2024). The comorbidity and co-medication profile of patients with progressive supranuclear palsy. J NEUROL, 271(2), 782–793. https://doi.org/10.1007/s00415-023-12006-4

Vancouver

Greten S, Wegner F, Jensen I, Krey L, Rogozinski S, Fehring M et al. The comorbidity and co-medication profile of patients with progressive supranuclear palsy. J NEUROL. 2024 Feb;271(2):782–793. https://doi.org/10.1007/s00415-023-12006-4

Bibtex

@article{3118daf36dbe4c3b93d55d85eb520654,
title = "The comorbidity and co-medication profile of patients with progressive supranuclear palsy",
abstract = "BACKGROUND: Progressive supranuclear palsy (PSP) is usually diagnosed in elderly. Currently, little is known about comorbidities and the co-medication in these patients.OBJECTIVES: To explore the pattern of comorbidities and co-medication in PSP patients according to the known different phenotypes and in comparison with patients without neurodegenerative disease.METHODS: Cross-sectional data of PSP and patients without neurodegenerative diseases (non-ND) were collected from three German multicenter observational studies (DescribePSP, ProPSP and DANCER). The prevalence of comorbidities according to WHO ICD-10 classification and the prevalence of drugs administered according to WHO ATC system were analyzed. Potential drug-drug interactions were evaluated using AiDKlinik{\textregistered}.RESULTS: In total, 335 PSP and 275 non-ND patients were included in this analysis. The prevalence of diseases of the circulatory and the nervous system was higher in PSP at first level of ICD-10. Dorsopathies, diabetes mellitus, other nutritional deficiencies and polyneuropathies were more frequent in PSP at second level of ICD-10. In particular, the summed prevalence of cardiovascular and cerebrovascular diseases was higher in PSP patients. More drugs were administered in the PSP group leading to a greater percentage of patients with polypharmacy. Accordingly, the prevalence of potential drug-drug interactions was higher in PSP patients, especially severe and moderate interactions.CONCLUSIONS: PSP patients possess a characteristic profile of comorbidities, particularly diabetes and cardiovascular diseases. The eminent burden of comorbidities and resulting polypharmacy should be carefully considered when treating PSP patients.",
author = "Stephan Greten and Florian Wegner and Ida Jensen and Lea Krey and Sophia Rogozinski and Meret Fehring and Johanne Heine and Johanna Doll-Lee and Monika P{\"o}tter-Nerger and Molly Zeitzschel and Keno Hagena and Pedrosa, {David J} and Carsten Eggers and Katrin B{\"u}rk and Claudia Trenkwalder and Inga Claus and Tobias Warnecke and Patrick S{\"u}{\ss} and J{\"u}rgen Winkler and Doreen Gruber and Florin Gandor and Daniela Berg and Steffen Paschen and Joseph Classen and Pinkhardt, {Elmar H} and Jan Kassubek and Jost, {Wolfgang H} and Lars T{\"o}nges and K{\"u}hn, {Andrea A} and Johannes Schwarz and Oliver Peters and Eman Dashti and Josef Priller and Spruth, {Eike J} and Patricia Krause and Annika Spottke and Anja Schneider and Aline Beyle and Okka Kimmich and Markus Donix and Robert Haussmann and Moritz Brandt and Elisabeth Dinter and Jens Wiltfang and Schott, {Bj{\"o}rn H} and Inga Zerr and Mathias B{\"a}hr and Katharina Buerger and Daniel Janowitz and Robert Perneczky and Boris-Stephan Rauchmann and Endy Weidinger and Johannes Levin and Sabrina Katzdobler and Emrah D{\"u}zel and Wenzel Glanz and Stefan Teipel and Ingo Kilimann and Johannes Prudlo and Thomas Gasser and Kathrin Brockmann and Hoffmann, {Daniel C} and Thomas Klockgether and Olaf Krause and Johannes Heck and H{\"o}glinger, {G{\"u}nter U} and Martin Klietz",
note = "{\textcopyright} 2023. The Author(s).",
year = "2024",
month = feb,
doi = "10.1007/s00415-023-12006-4",
language = "English",
volume = "271",
pages = "782–793",
journal = "J NEUROL",
issn = "0340-5354",
publisher = "D. Steinkopff-Verlag",
number = "2",

}

RIS

TY - JOUR

T1 - The comorbidity and co-medication profile of patients with progressive supranuclear palsy

AU - Greten, Stephan

AU - Wegner, Florian

AU - Jensen, Ida

AU - Krey, Lea

AU - Rogozinski, Sophia

AU - Fehring, Meret

AU - Heine, Johanne

AU - Doll-Lee, Johanna

AU - Pötter-Nerger, Monika

AU - Zeitzschel, Molly

AU - Hagena, Keno

AU - Pedrosa, David J

AU - Eggers, Carsten

AU - Bürk, Katrin

AU - Trenkwalder, Claudia

AU - Claus, Inga

AU - Warnecke, Tobias

AU - Süß, Patrick

AU - Winkler, Jürgen

AU - Gruber, Doreen

AU - Gandor, Florin

AU - Berg, Daniela

AU - Paschen, Steffen

AU - Classen, Joseph

AU - Pinkhardt, Elmar H

AU - Kassubek, Jan

AU - Jost, Wolfgang H

AU - Tönges, Lars

AU - Kühn, Andrea A

AU - Schwarz, Johannes

AU - Peters, Oliver

AU - Dashti, Eman

AU - Priller, Josef

AU - Spruth, Eike J

AU - Krause, Patricia

AU - Spottke, Annika

AU - Schneider, Anja

AU - Beyle, Aline

AU - Kimmich, Okka

AU - Donix, Markus

AU - Haussmann, Robert

AU - Brandt, Moritz

AU - Dinter, Elisabeth

AU - Wiltfang, Jens

AU - Schott, Björn H

AU - Zerr, Inga

AU - Bähr, Mathias

AU - Buerger, Katharina

AU - Janowitz, Daniel

AU - Perneczky, Robert

AU - Rauchmann, Boris-Stephan

AU - Weidinger, Endy

AU - Levin, Johannes

AU - Katzdobler, Sabrina

AU - Düzel, Emrah

AU - Glanz, Wenzel

AU - Teipel, Stefan

AU - Kilimann, Ingo

AU - Prudlo, Johannes

AU - Gasser, Thomas

AU - Brockmann, Kathrin

AU - Hoffmann, Daniel C

AU - Klockgether, Thomas

AU - Krause, Olaf

AU - Heck, Johannes

AU - Höglinger, Günter U

AU - Klietz, Martin

N1 - © 2023. The Author(s).

PY - 2024/2

Y1 - 2024/2

N2 - BACKGROUND: Progressive supranuclear palsy (PSP) is usually diagnosed in elderly. Currently, little is known about comorbidities and the co-medication in these patients.OBJECTIVES: To explore the pattern of comorbidities and co-medication in PSP patients according to the known different phenotypes and in comparison with patients without neurodegenerative disease.METHODS: Cross-sectional data of PSP and patients without neurodegenerative diseases (non-ND) were collected from three German multicenter observational studies (DescribePSP, ProPSP and DANCER). The prevalence of comorbidities according to WHO ICD-10 classification and the prevalence of drugs administered according to WHO ATC system were analyzed. Potential drug-drug interactions were evaluated using AiDKlinik®.RESULTS: In total, 335 PSP and 275 non-ND patients were included in this analysis. The prevalence of diseases of the circulatory and the nervous system was higher in PSP at first level of ICD-10. Dorsopathies, diabetes mellitus, other nutritional deficiencies and polyneuropathies were more frequent in PSP at second level of ICD-10. In particular, the summed prevalence of cardiovascular and cerebrovascular diseases was higher in PSP patients. More drugs were administered in the PSP group leading to a greater percentage of patients with polypharmacy. Accordingly, the prevalence of potential drug-drug interactions was higher in PSP patients, especially severe and moderate interactions.CONCLUSIONS: PSP patients possess a characteristic profile of comorbidities, particularly diabetes and cardiovascular diseases. The eminent burden of comorbidities and resulting polypharmacy should be carefully considered when treating PSP patients.

AB - BACKGROUND: Progressive supranuclear palsy (PSP) is usually diagnosed in elderly. Currently, little is known about comorbidities and the co-medication in these patients.OBJECTIVES: To explore the pattern of comorbidities and co-medication in PSP patients according to the known different phenotypes and in comparison with patients without neurodegenerative disease.METHODS: Cross-sectional data of PSP and patients without neurodegenerative diseases (non-ND) were collected from three German multicenter observational studies (DescribePSP, ProPSP and DANCER). The prevalence of comorbidities according to WHO ICD-10 classification and the prevalence of drugs administered according to WHO ATC system were analyzed. Potential drug-drug interactions were evaluated using AiDKlinik®.RESULTS: In total, 335 PSP and 275 non-ND patients were included in this analysis. The prevalence of diseases of the circulatory and the nervous system was higher in PSP at first level of ICD-10. Dorsopathies, diabetes mellitus, other nutritional deficiencies and polyneuropathies were more frequent in PSP at second level of ICD-10. In particular, the summed prevalence of cardiovascular and cerebrovascular diseases was higher in PSP patients. More drugs were administered in the PSP group leading to a greater percentage of patients with polypharmacy. Accordingly, the prevalence of potential drug-drug interactions was higher in PSP patients, especially severe and moderate interactions.CONCLUSIONS: PSP patients possess a characteristic profile of comorbidities, particularly diabetes and cardiovascular diseases. The eminent burden of comorbidities and resulting polypharmacy should be carefully considered when treating PSP patients.

U2 - 10.1007/s00415-023-12006-4

DO - 10.1007/s00415-023-12006-4

M3 - SCORING: Journal article

C2 - 37803149

VL - 271

SP - 782

EP - 793

JO - J NEUROL

JF - J NEUROL

SN - 0340-5354

IS - 2

ER -